Slide 1: Q1 2026 Earnings Call
Q1 2026 Earnings Call May 13, 2026
Slide 2: Safe harbor disclosures
Safe harbor disclosures Forward Looking Statements The forward-looking statements in this presentation are made only as of the date hereof. For a further Certain statements in this presentation and the accompanying oral commentary are forward-looking description of the risks and uncertainties that c
Slide 3: Growing evidence base driving increasing Proteograph adoption
Growing evidence base driving increasing Proteograph adoption Growing external validation Researchers are makes us a trusted partner Cumulative peer-reviewed demonstrating differentiated publications Proteograph insights 84 customer publications, U.S HUPO Conference 2026 preprints and reviews1 84 •
Slide 4: Nature Communications authors leveraged the Proteograph for cross-ancestry comparison
Nature Communications authors leveraged the Proteograph to perform cross-ancestry comparison of aptamer and antibody protein measures Meaningful fraction of “protein associations” in large-scale affinity proteomics are being driven by protein-altering variants that change binding and epitope behavio
Slide 5: Furthering the adoption of proteomics by enabling deep, unbiased population-scale studies
Furthering the adoption of proteomics by enabling deep, unbiased population-scale studies 10,000-sample study secured in collaboration with Precision Health Research, Singapore Large-scale multiomics study funded by the NIH 10,000-sample study secured in collaboration with Discovery Life Sciences 20
Slide 6: Insights Grant Program expansion to two tracks, including new focus on biopharma development
Insights Grant Program expansion to two tracks, including new focus on biopharma development Translational Research Biopharma Development Continues the translational work New track designed to engage that has generated strong pharma and biotech teams in scientific returns and publications workflows
Slide 7: A strong track record of innovation with a robust product pipeline ahead
A strong track record of innovation with a robust product pipeline ahead 2021 2022 2023 2024 2025 2026 2027+ Instrument Instrument Instrument SP100 Launch SP200 Launch Next-Generation Detector Assay Assay Assay Assay RiSE XT ONE Proteoform Profiling Assay Kit Software Software Software Software PAS
Slide 8: Q1 2026 financial overview
Q1 2026 financial overview Q1’26 Q1’25 Revenue $2.8M $4.2M ~$220M Product & Service Revenue $2.6M $4.1M Cash, cash equivalents and investments, no debt1 Related Party Revenue $0.1M $0.1M Other Revenue $0.1M $0.1M Gross Margin 35% 49% ~1.5M Operating Expenses $18.2M $22.8M shares Stock-Based Compensa
Slide 9: Reiterating full year 2026 revenue guidance
Reiterating full year 2026 revenue guidance $16M - $18M ~3% y/y growth at midpoint 9
Slide 10: 2026 growth catalysts
2026 growth catalysts Expand addressable Win additional market through new population-scale product innovation cohort programs Revenue growth Establish leadership Grow and drive utilization position as preferred of rapidly expanding proteomic data platform installed base for AI-driven biology 10 © 2
Slide 11: Slide 11